Russia’s Covid-19 vaccine showed antibody response in initial trials: Lancet study
Team Udayavani, Sep 5, 2020, 4:03 PM IST
Russia’s new Covid-19 vaccine has passed early trial test and the patients involved in early tests developed antibodies with no serious adverse effects
A research article published in The Lancet reported that two small trials, each involving 38 healthy adults aged between 18 and 60, were given a two-part immunisation.
As per the report, the participants were monitored over 42 days and all developed antibodies within the first three weeks.
Also, over 76 participants of these trials would be monitored up to 180 days and more rigorous phase 3 clinical trial was planned with the involvement of 40,000 volunteers from different age and risk groups.
The data showed that the vaccine was “safe, well tolerated, and does not cause serious adverse events in healthy adult volunteers”.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
World Malaria Day: WHO calls for equitable health access
What role does genetics play in breast cancer? How can genetic testing help with early breast cancer diagnosis?
Father’s diet can affect anxiety in sons, metabolism in daughters: Study in mice finds
Low back pain, depression, headaches main causes of poor health: Study
Surgical options for Parkinson’s disease
MUST WATCH
Latest Additions
Firing outside Salman Khan’s residence: Cops arrest 2 more from Punjab who supplied weapons to shooters
BJP’s progress stalled in resolving Darjeeling hills political issue: Congress
People urged to reject BJD for Odisha’s progress: Shah
PM Modi takes aim at Rahul Gandhi and Akhilesh Yadav for alleged politics of appeasement
Delhi HC adjourns hearing on Facebook, WhatsApp pleas challenging IT rules on traceability to August